scholarly journals Protective effect of alpha lipoic acid on diabetic nephropathy in rats

2019 ◽  
Vol 20 (3) ◽  
pp. 19-23
Author(s):  
Samar Yabes ◽  
Mohamed EL-Adl ◽  
Mohamed Hamed ◽  
Gehad El-Sayed
Keyword(s):  
Diabetic Nephropathy ◽  
Lipoic Acid ◽  
Nitrosative Stress ◽  
Acid Group ◽  
Controlled Study ◽  
Alpha Lipoic Acid ◽  
Sprague Dawley ◽  
Glycemic Status ◽  
Oxidative And Nitrosative Stress ◽  
Tissue Samples

Objective: To evaluate the protective role of alpha lipoic acid in rats affected with experimentally-induced diabetes and secondarily complicated with nephropathy. Design: Randomized controlled study. Animals: Forty-eight Sprague Dawley rats. Procedures: Rats were allocated randomly into four groups (12 each); Control rats (Group 1); alpha lipoic acid (ALA) supplemented rats (Group 2); rats with induced diabetic nephropathy (Group 3), and rats with diabetic nephropathy and supplemented with alpha lipoic acid (Group 4). After one month of experimental induction, serum, plasma and renal tissue samples were harvested to determine glycemic status, renal damage markers, antioxidant status, oxidative and nitrosative stress markers, apoptotic marker and histopathology of kidney tissues. Results: In comparison with non-supplemented diabetic rats, alpha lipoic acid reduced renal malondialdehyde (5.74± 0.26 vs 11.3± 1.96 nmol/g. tissue) and renal nitric oxide (30.06± 2.07 vs 36.6± 1.07 nmol/g. tissue). ALA significantly improved the antioxidant enzyme activity (catalase and reduced glutathione), glycemic status, and decreased caspase 3 concentration (P<0.05). Conclusion and clinical relevance: Alpha lipoic acid may be an alternative intervention to alleviate nephropathy as a complication of diabetes. Further studies need to be done in naturally occurring cases.

Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study

2020 ◽  
Vol 20 (9) ◽  
pp. 1531-1534 ◽  
Author(s):  
Mamdouh R. El-Nahas ◽  
Ghada Elkannishy ◽  
Hala Abdelhafez ◽  
Enas T. Elkhamisy ◽  
Amr A. El-Sehrawy
Keyword(s):  
Peripheral Neuropathy ◽  
Lipoic Acid ◽  
Diabetic Peripheral Neuropathy ◽  
Study Groups ◽  
Controlled Study ◽  
Alpha Lipoic Acid ◽  
Disability Score ◽  
Perception Threshold ◽  
Outcome Parameters ◽  
Double Blinded

Background: Alpha-lipoic acid (ALA) was used in the treatment of diabetic peripheral neuropathy (DPN) using different routes, doses and treatment durations. The aim of this work is to assess the efficacy of oral 600mg ALA twice daily over 6 months in the treatment of patients with DPN. Methods: This is a prospective, single-center, double-blinded, placebo-controlled study conducted at the outpatient clinic of Mansoura Specialized Hospital, Mansoura University. A total of 200 patients with DPN were randomly assigned to add on treatment with either oral 600mg twice daily ALA (n=100) or placebo (n=100) for 6 months. Treatment outcome was assessed using vibration perception threshold (VPT), neurological symptom score (NSS), neurological disability score (NDS), and visual analog scale (VAS) for pain at baseline and at each visit (1, 3 and 6 months) after the start of treatment. Results: Comparison between the study groups regarding the baseline data revealed no statistically significant differences. with respect to the outcome parameters, no significant differences were found between the studied groups at baseline. However, in subsequent visits, ALA-treated patients had significantly better results regarding almost all the outcome parameters (NSS, NDS, VAS, VPT). Mild nausea was reported in 6 patients. None of the studied patients discontinued treatment. Conclusions: Oral 600mg ALA twice-daily treatment for DPN over 6 months is effective, safe and tolerable.

The effect of alpha lipoic acid supplementation on sperm functions in idiopathic asthenozoospermic patients: a case-controlled study

2022 ◽  
pp. 1-9
Author(s):  
Yahya M. Hodeeb ◽  
Emad M. El-Rewiny ◽  
Abdullah M. Gaafar ◽  
Ahmed N. Zayed ◽  
Mohamed S. Hasan ◽  
...  
Keyword(s):  
Lipoic Acid ◽  
Controlled Study ◽  
Alpha Lipoic Acid ◽  
Acid Supplementation ◽  
Sperm Functions

scholarly journals The effects of alpha-lipoic acid supplementation on diabetic nephropathy in humans

2020 ◽  
Author(s):  
Eleni Vakali ◽  
Dimitrios Rigopoulos ◽  
Andres Carrillo ◽  
Andreas Flouris ◽  
Petros Dinas
Keyword(s):  
Diabetic Nephropathy ◽  
Lipoic Acid ◽  
Alpha Lipoic Acid ◽  
Acid Supplementation

scholarly journals N-acetylcysteine protects against diabetic nephropathy through control of oxidative and nitrosative stress by recovery of nitric oxide in rats

Nitric Oxide ◽  
2018 ◽  
Vol 78 ◽  
pp. 22-31 ◽  
Author(s):  
Guilherme B. Nogueira ◽  
Giovana R. Punaro ◽  
Clemerson S. Oliveira ◽  
Fabiane R. Maciel ◽  
Thamires O. Fernandes ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Diabetic Nephropathy ◽  
Nitrosative Stress ◽  
Oxidative And Nitrosative Stress

Effects of alpha-lipoic acid supplementation on human diabetic nephropathy: A systematic review and meta-analysis

2021 ◽  
Vol 17 ◽  
Author(s):  
Elena Vakali ◽  
Dimitrios Rigopoulos ◽  
Andres E. Carrillo ◽  
Andreas D. Flouris ◽  
Petros C. Dinas
Keyword(s):  
Systematic Review ◽  
Diabetic Nephropathy ◽  
Lipoic Acid ◽  
Excretion Rate ◽  
Meta Analysis ◽  
Alpha Lipoic Acid ◽  
Creatinine Ratio ◽  
Biological Indices ◽  
Urine Albumin ◽  
Patients With Diabetes

Background: Diabetic nephropathy (DN) is a kidney dysfunction, which occurs due to elevated urine albumin excretion rate and reduced glomerular filtration rate. Studies in animals have shown that alpha-lipoic acid (ALA) supplementation can reduce the development of DN. Objectives: We performed a systematic review and meta-analysis to examine the effects of ALA supplementation on biological indices (albumin, creatinine etc.) indicative of human DN. Methods: The searching procedure included the databases PubMed Central, Embase, Cochrane Library (trials) and Web of Science, (protocol registration: INPLASY 202060095). Results: We found that ALA supplementation decreased urine albumin 24h excretion rate in patients with diabetes [standardized mean difference=-2.27; confidence interval (CI)=(-4.09)–(-0.45); I2=98%; Z=2.44; p=0.01]. A subgroup analysis revealed that the studies examining only ALA, did not differ from those examined ALA in combination with additional medicines (Chi-squared=0.19; p=0.66; I2=0%), while neither ALA nor ALA plus medication had an effect on urine albumin 24h excretion rate (p>0.05). Also, ALA supplementation decreased urine albumin mg/l [mean difference (MD)=-12.95; CI=(-23.88)–(-2.02); I2=44%; Z=2.32; p=0.02] and urine albumin to creatinine ratio [MD=-26.96; CI=(-35.25)–(-18.67); I2=0%; Z=6.37; p<0.01] in patients with diabetes. When the studies that examined ALA plus medication were removed, ALA supplementation had no effect on urine albumin mg/l (p>0.05), but did significantly decrease urine albumin to creatinine ratio [MD=-25.88, CI=(34.40–(-17.36), I2=0%, Z=5.95, p<0.00001]. Conclusion: The available evidence suggests that ALA supplementation does not improve biological indices that reflect DN in humans. Overall, we identified limited evidence and therefore, the outcomes should be considered with caution.

Sex differences in nitrosative stress during renal ischemia

2010 ◽  
Vol 299 (5) ◽  
pp. R1387-R1395 ◽  
Author(s):  
Francisca Rodríguez ◽  
Susana Nieto-Cerón ◽  
Francisco J. Fenoy ◽  
Bernardo López ◽  
Isabel Hernández ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Sex Differences ◽  
Nitric Oxide Synthase ◽  
Nitrosative Stress ◽  
Differential Pulse ◽  
Sprague Dawley ◽  
Oxidative And Nitrosative Stress ◽  
Sprague Dawley Rats ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

Females. suffer a less severe ischemic acute renal failure than males, apparently because of higher nitric oxide (NO) bioavailability and/or lower levels of oxidative stress. Because the renal ischemic injury is associated with outer medullary (OM) endothelial dysfunction, the present study evaluated sex differences in OM changes of NO and peroxynitrite levels (by differential pulse voltammetry and amperometry, respectively) during 45 min of ischemia and 60 min of reperfusion in anesthetized Sprague-Dawley rats. Endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) protein expression and their phosphorylated forms [peNOS(Ser1177) and pnNOS(Ser1417)], 3-nitrotyrosine, reduced sulfhydryl groups (-SH), and glomerular filtration rate (GFR) were also determined. No sex differences were observed in monomeric eNOS and nNOS expression, NO, or 3-nitrotyrosine levels in nonischemic kidneys, but renal -SH content was higher in females. Ischemia increased dimeric/monomeric eNOS and nNOS ratio more in females, but the dimeric phosphorylated peNOS(Ser1177) and pnNOS(Ser1417) forms rose similarly in both sexes, indicating no sex differences in nitric oxide synthase activation. However, NO levels increased more in females than in males (6,406.0 ± 742.5 and 4,058.2 ± 272.35 nmol/l respectively, P < 0.05), together with a lower increase in peroxynitrite current (5.5 ± 0.7 vs. 12.7 ± 1.5 nA, P < 0.05) and 3-nitrotyrosine concentration, (28.7 ± 3.7 vs. 48.7 ± 3.7 nmol/mg protein, P < 0.05) in females than in males and a better preserved GFR after ischemia in females than in males (689.7 ± 135.0 and 221.4 ± 52.5 μl·min−1·g kidney wt−1, P < 0.01). Pretreatment with the antioxidants N-acetyl-l-cysteine or ebselen abolished sex differences in peroxynitrite, nitrotyrosine, and GFR, suggesting that a greater oxidative and nitrosative stress worsens renal damage in males.

Sign in / Sign up

Export Citation Format

Share Document